Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/PRKACB_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PRKACB_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PRKACB_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PRKACB_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PRKACB_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PRKACB_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PRKACB_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PRKACB_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007217515 | Thyroid | PTC | epithelial tube formation | 66/5968 | 132/18723 | 1.08e-05 | 1.19e-04 | 66 |
GO:00163318 | Thyroid | PTC | morphogenesis of embryonic epithelium | 71/5968 | 147/18723 | 2.31e-05 | 2.29e-04 | 71 |
GO:00164859 | Thyroid | PTC | protein processing | 95/5968 | 225/18723 | 6.60e-04 | 4.15e-03 | 95 |
GO:0045879 | Thyroid | PTC | negative regulation of smoothened signaling pathway | 17/5968 | 32/18723 | 1.02e-02 | 4.11e-02 | 17 |
GO:004578614 | Thyroid | ATC | negative regulation of cell cycle | 181/6293 | 385/18723 | 2.64e-08 | 5.07e-07 | 181 |
GO:006056222 | Thyroid | ATC | epithelial tube morphogenesis | 156/6293 | 325/18723 | 4.48e-08 | 8.14e-07 | 156 |
GO:000184119 | Thyroid | ATC | neural tube formation | 59/6293 | 102/18723 | 4.28e-07 | 6.25e-06 | 59 |
GO:002191515 | Thyroid | ATC | neural tube development | 80/6293 | 152/18723 | 9.87e-07 | 1.29e-05 | 80 |
GO:0051604110 | Thyroid | ATC | protein maturation | 136/6293 | 294/18723 | 4.00e-06 | 4.42e-05 | 136 |
GO:000183823 | Thyroid | ATC | embryonic epithelial tube formation | 65/6293 | 121/18723 | 4.02e-06 | 4.43e-05 | 65 |
GO:001402017 | Thyroid | ATC | primary neural tube formation | 53/6293 | 94/18723 | 4.69e-06 | 5.11e-05 | 53 |
GO:000184316 | Thyroid | ATC | neural tube closure | 50/6293 | 88/18723 | 6.43e-06 | 6.68e-05 | 50 |
GO:006060616 | Thyroid | ATC | tube closure | 50/6293 | 89/18723 | 9.90e-06 | 9.87e-05 | 50 |
GO:007217522 | Thyroid | ATC | epithelial tube formation | 68/6293 | 132/18723 | 1.59e-05 | 1.48e-04 | 68 |
GO:001633114 | Thyroid | ATC | morphogenesis of embryonic epithelium | 74/6293 | 147/18723 | 1.96e-05 | 1.77e-04 | 74 |
GO:003514823 | Thyroid | ATC | tube formation | 74/6293 | 148/18723 | 2.65e-05 | 2.27e-04 | 74 |
GO:001648515 | Thyroid | ATC | protein processing | 100/6293 | 225/18723 | 4.39e-04 | 2.62e-03 | 100 |
GO:00458791 | Thyroid | ATC | negative regulation of smoothened signaling pathway | 20/6293 | 32/18723 | 7.67e-04 | 4.24e-03 | 20 |
GO:0008589 | Thyroid | ATC | regulation of smoothened signaling pathway | 40/6293 | 81/18723 | 2.36e-03 | 1.10e-02 | 40 |
GO:0007224 | Thyroid | ATC | smoothened signaling pathway | 60/6293 | 138/18723 | 9.75e-03 | 3.57e-02 | 60 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRKACB | SNV | Missense_Mutation | novel | c.658C>A | p.Leu220Ile | p.L220I | P22694 | protein_coding | tolerated(0.43) | benign(0.089) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRKACB | SNV | Missense_Mutation | | c.732N>T | p.Trp244Cys | p.W244C | P22694 | protein_coding | deleterious(0) | benign(0.102) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRKACB | SNV | Missense_Mutation | | c.1022N>A | p.Thr341Asn | p.T341N | P22694 | protein_coding | tolerated(1) | benign(0) | TCGA-CM-4748-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | fluorouracil | SD |
PRKACB | SNV | Missense_Mutation | novel | c.260N>A | p.Gly87Glu | p.G87E | P22694 | protein_coding | tolerated(0.27) | benign(0.003) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PRKACB | SNV | Missense_Mutation | | c.515C>A | p.Pro172His | p.P172H | P22694 | protein_coding | tolerated(0.11) | possibly_damaging(0.833) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRKACB | SNV | Missense_Mutation | novel | c.565N>A | p.Pro189Thr | p.P189T | P22694 | protein_coding | deleterious(0.05) | benign(0.066) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRKACB | SNV | Missense_Mutation | rs148797911 | c.259N>A | p.Gly87Arg | p.G87R | P22694 | protein_coding | tolerated(0.13) | benign(0.005) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PRKACB | SNV | Missense_Mutation | novel | c.574C>T | p.Arg192Trp | p.R192W | P22694 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
PRKACB | SNV | Missense_Mutation | novel | c.68A>G | p.Glu23Gly | p.E23G | P22694 | protein_coding | tolerated_low_confidence(0.06) | benign(0.223) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
PRKACB | SNV | Missense_Mutation | | c.341A>C | p.Glu114Ala | p.E114A | P22694 | protein_coding | tolerated(0.27) | benign(0.015) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5567 | PRKACB | ENZYME, KINASE, CLINICALLY ACTIONABLE, G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, SERINE THREONINE KINASE | inhibitor | 178101884 | GSK-690693 | |
5567 | PRKACB | ENZYME, KINASE, CLINICALLY ACTIONABLE, G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, SERINE THREONINE KINASE | | FASUDIL | FASUDIL | 22257127 |
5567 | PRKACB | ENZYME, KINASE, CLINICALLY ACTIONABLE, G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, SERINE THREONINE KINASE | inhibitor | 135652717 | STAUROSPORINE | |
5567 | PRKACB | ENZYME, KINASE, CLINICALLY ACTIONABLE, G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, SERINE THREONINE KINASE | inhibitor | CHEMBL494089 | GSK-690693 | |